The Engineering Biology Advisory Committee (EBAC) is composed of industry experts in engineering/synthetic biology and provides a forum for BIA members to discuss and keep abreast of the key issues associated with the rapidly increasing pace with which we can engineer biology.

2021 priorities


  • Represent the UK engineering biology sector at both UK and international conferences, e.g. SynbiTECH and organise a session at the Bioscience Forum
  • Coordinate activities with stakeholders across the sector, including the Engineering Biology Leadership Council and the Royal Academy of Engineering


  • Work with funders and civil servants as the UKRI National Engineering Biology Programme is developed further
  • Support BIA lobbying activities through its activities at Parliament Day, the representation of member views concerning the Comprehensive Spending Review, and new government proposals to modify the regulatory framework for GM activities
  • Provide input into the BIA’s work on the National Security and Investment Bill and monitor the new regime’s implications on UK engineering biology
  • Inform the BIA’s skills work to ensure the interests and needs of engineering biology companies are represented

Expert advice:

  • Lead on BIA’s efforts to stop the inclusion of digital sequence information into the Nagoya Protocol
  • Support the growth and development of SMEs in engineering biology, including facilitating engagement with investors and funders, connecting SMEs with biomanufacturers, and keeping SMEs updated on the regulatory environment

Committee Chair: Tim Brears, CEO, Evonetix

Committee Vice-chair: Edward Green, CEO, CHAIN Biotechnology 

For more information please contact Eric Johnsson, Policy and Public Affairs Manager

Member list

Arnold & Porter


Basecamp Research


Centre for Process Innovation

The Centre for Process Innovation is a UK-based technology innovation centre and part of the High Value Manufacturing Catapult.

Chain Biotechnology Ltd

Chain Biotech is a UK start-up company providing synthetic biology tools and underpinning services for the bioscience community.

Earlham Institute

Engineering Biology Leadership Council


Evonetix is developing a novel, highly disruptive approach to gene synthesis, the technology which underpins the rapidly growing field of synthetic biology.


GSK is a global pharmaceutical company dedicated to helping people feel better, do more and live longer.

Ingenza Ltd

Ingenza Ltd. is an industrial biotechnology company based in Roslin, Edinburgh, UK. The company has a broad customer base within the chemicals, pharmaceuticals, food, feed and fuel industries where it applies its proprietary synthetic biology to manufacture industrial products.

Knowledge Transfer Network


LGC is an international science-based company and market leader in analytical, forensic, biotechnology, diagnostic and product services and reference standards.

National Physical Laboratory

Prokarium Ltd

Prokarium’s Vaxonella platform enables almost any protein vaccine to be delivered to and produced from within the body’s own immune cells.



SynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry.



Synthace is an applied synthetic biology company which bioengineers micro-organisms for the production of high value chemical products.

Taylor Wessing

Taylor Wessing is a powerful source of legal support for commercial organisations doing business in and with Europe. With 165 partners and around 1000 staff based principally in the UK and Germany, Taylor Wessing provides the full range of legal services to major corporations and growing enterprises. Highly regarded for its record in corporate and IP transactions, Taylor Wessing has also earned a strong market presence in corporate finance, private equity, real estate finance and inward investment.

Thermo Fisher Scientific

Touchlight Genetics Ltd

Touchlight Genetics is a UK based DNA technology company. We collaborate with leading research institutes to create new DNA therapeutics.